How do you manage a breast cancer patient with discordance in hormone receptor status with IHC and Oncotype?

Given the therapeutic window of endocrine therapy, and evidence of efficacy at even low ER expression (but not no expression!), the bar is set low for use of ET. IHC staining is the gold standard and I treat accordingly, so a tumor that is positive on staining for ER but negative on the single RNA b...